Does OSIMERTINIB Cause Myelosuppression? 510 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 510 reports of Myelosuppression have been filed in association with OSIMERTINIB (TAGRISSO). This represents 1.8% of all adverse event reports for OSIMERTINIB.
510
Reports of Myelosuppression with OSIMERTINIB
1.8%
of all OSIMERTINIB reports
10
Deaths
166
Hospitalizations
How Dangerous Is Myelosuppression From OSIMERTINIB?
Of the 510 reports, 10 (2.0%) resulted in death, 166 (32.5%) required hospitalization, and 30 (5.9%) were considered life-threatening.
Is Myelosuppression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OSIMERTINIB. However, 510 reports have been filed with the FAERS database.
What Other Side Effects Does OSIMERTINIB Cause?
Death (10,423)
Malignant neoplasm progression (2,920)
Diarrhoea (1,408)
Drug resistance (1,026)
Fatigue (819)
Rash (772)
Decreased appetite (706)
Drug ineffective (627)
Dyspnoea (621)
Nausea (610)
What Other Drugs Cause Myelosuppression?
CYCLOPHOSPHAMIDE (3,603)
CARBOPLATIN (2,624)
TRASTUZUMAB (2,552)
PACLITAXEL (2,522)
TISLELIZUMAB (2,142)
CYTARABINE (1,869)
VENETOCLAX (1,864)
CISPLATIN (1,849)
BEVACIZUMAB (1,744)
SODIUM (1,696)
Which OSIMERTINIB Alternatives Have Lower Myelosuppression Risk?
OSIMERTINIB vs OSPEMIFENE
OSIMERTINIB vs OSPHENA
OSIMERTINIB vs OVINE DIGOXIN IMMUNE FAB
OSIMERTINIB vs OXACILLIN
OSIMERTINIB vs OXALIPLATIN